EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biomarker Assessment in Parkinson’s Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures

Giovanni R Malaty, Boris Decourt, Holly A Shill, Marwan N Sabbagh

Journal of Alzheimer's Disease Reports · 09.01.2024 · 8 (1) · 1361-1371

DOI: 10.3233/adr-240110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 25.10.2024. Verfasst von Giovanni R Malaty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plasma biomarker assays provide an opportunity to reassess whether Alzheimer’s disease, Parkinson’s disease dementia (PDD), and dementia with Lewy bodies (DLB) plasma biomarkers are diagnostically useful.

Objective

We hypothesized that immunomagnetic reduction (IMR) of plasma biomarkers could differentiate between patients with PDD and DLB and healthy patients when combined with established clinical testing measures.

Methods

Plasma samples from 61 participants (12 PDD, 12 DLB, 37 controls) were analyzed using IMR to quantify amyloid-β 42 (Aβ 42 ), total tau (t-tau), phosphorylated tau at threonine 181 (p-tau181), and α-synuclein (α-syn). Receiver operating characteristic curve (ROC) analysis was used to obtain sensitivity, specificity, and area under the ROC curve. Biomarker results were combined with clinical measures from the Unified Parkinson’s Disease Rating Scale (UPDRS), Montreal Cognitive Assessment, and Hoehn-Yahr stage to optimize diagnostic test performance.

Results

Participants with PDD had higher α-syn than those with DLB and healthy participants and were distinguishable by their biomarker products Aβ 42 ×p-tau181 and Aβ 42 ×α-syn. Patients with DLB had higher p-tau181 than those with PDD and healthy participants and were distinguishable by their concentrations of α-syn×p-tau181. Plasma α-syn plus UPDRS versus either test alone increased sensitivity, specificity, and AUC when healthy patients were compared with those with PDD and DLB. Combined clinical examination scores and plasma biomarker products demonstrated utility in differentiating PDD from DLB when p-tau181 was combined with UPDRS, α-syn was combined with UPDRS, and α-syn×p-tau181 was combined with UPDRS.

Conclusions

In this pilot study, IMR plasma p-tau181 and α-syn may discriminate between PDD and DLB when used in conjunction with clinical testing.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseParkinson’s disease dementiaUnified Parkinson’s Disease Rating Scaledementia with Lewy bodiesimmunomagnetic reduction assayp-tau181α-synuclein

Autor:innen und Institutionen

  • Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
  • Department of Pharmacology and Neurosciences, Health Sciences Center, Texas Tech University, Lubbock, TX, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Malaty, G. R., Decourt, B., Shill, H. A., & Sabbagh, M. N. (2024). Biomarker Assessment in Parkinson’s Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures. Journal of Alzheimer's Disease Reports, 8(1), 1361-1371. https://doi.org/10.3233/adr-240110

Vancouver

Malaty GR, Decourt B, Shill HA, Sabbagh MN. Biomarker Assessment in Parkinson’s Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures. Journal of Alzheimer's Disease Reports. 2024;8(1):1361-1371. doi:10.3233/adr-240110

BibTeX
@article{Malaty2024,
  author = {Malaty, Giovanni R and Decourt, Boris and Shill, Holly A and Sabbagh, Marwan N},
  title = {Biomarker Assessment in Parkinson’s Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures},
  journal = {Journal of Alzheimer's Disease Reports},
  year = {2024},
  volume = {8},
  number = {1},
  pages = {1361--1371},
  doi = {10.3233/adr-240110}
}
Kostenlos starten →